Q2 2024 · 13F-HR/A
Novo Holdings A/Sholdings as filed
Filed 2024-08-20 · accession 0000950123-24-008900
$1.85B
Reported value
38
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922908769 | VTI | VANGUARD INDEX FDS | $277.8M | 15.0% | 1,038,550 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $161.2M | 8.69% | 3,880,230 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $142.6M | 7.69% | 4,074,419 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $136.4M | 7.35% | 133,336 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $123.4M | 6.66% | 480,160 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $114.3M | 6.16% | 6,344,430 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $78.3M | 4.22% | 2,411,362 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $71.7M | 3.87% | 950,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $53.6M | 2.89% | 800,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $51.3M | 2.76% | 1,500,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $44.8M | 2.41% | 1,000,000 | Common | SOLE |
| 12685J105 | CABO | CABLE ONE INC | $41.9M | 2.26% | 118,403 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $40.3M | 2.17% | 490,000 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $39.9M | 2.15% | 675,000 | Common | SOLE |
| 037833100 | AAPL | APPLE INC | $38.5M | 2.08% | 182,960 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $36.1M | 1.94% | 500,827 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $32.4M | 1.75% | 1,725,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $31.5M | 1.70% | 850,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $29.4M | 1.58% | 1,400,000 | Common | SOLE |
| 51655R101 | — | LANZATECH GLOBAL INC | $29.3M | 1.58% | 15,814,845 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $28.8M | 1.55% | 118,383 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $27.8M | 1.50% | 1,500,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $26.0M | 1.40% | 2,000,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $25.4M | 1.37% | 1,544,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $24.8M | 1.34% | 2,500,000 | Common | SOLE |
| 113004105 | BAM | BROOKFIELD ASSET MANAGMT LTD | $23.9M | 1.29% | 627,207 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $23.7M | 1.28% | 1,100,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $23.3M | 1.25% | 1,450,500 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $18.9M | 1.02% | 175,000 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $13.1M | 0.71% | 1,750,000 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HLDG INC | $12.8M | 0.69% | 375,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $11.7M | 0.63% | 2,400,000 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $7.3M | 0.40% | 1,800,000 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $5.2M | 0.28% | 4,429,449 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $3.3M | 0.18% | 1,126,915 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $2.4M | 0.13% | 441,558 | Common | SOLE |
| 36322Q107 | GLTOUSD | GALECTO INC | $1.2M | 0.06% | 2,497,791 | Common | SOLE |
| 84833T103 | SPRO | SPERO THERAPEUTICS INC | $609,573 | 0.03% | 468,902 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.